Marwan Sabbagh

MCLENA-1: lenalidomide in mild cognitive impairment due to Alzheimer’s disease 2:26
MCLENA-1: lenalidomide in mild cognitive impairment due to Alzheimer’s disease
Marwan Sabbagh • 8 Mar 2021
Second generation of anti-amyloid monoclonal antibodies for Alzheimer’s disease 1:28
Second generation of anti-amyloid monoclonal antibodies for Alzheimer’s disease
Marwan Sabbagh • 8 Mar 2021
Timely and accurate diagnosis of Alzheimer’s disease as the field evolves 0:59
Timely and accurate diagnosis of Alzheimer’s disease as the field evolves
Marwan Sabbagh • 8 Mar 2021
ALZ-801: oral anti-amyloid agent for Alzheimer’s disease 1:38
ALZ-801: oral anti-amyloid agent for Alzheimer’s disease
Marwan Sabbagh • 8 Mar 2021
APOE and TOMM40 as risk factors for Alzheimer’s disease 2:25
APOE and TOMM40 as risk factors for Alzheimer’s disease
Marwan Sabbagh • 8 Mar 2021
The content of VJNeurology is intended for healthcare professionals